The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy

Antibodies against checkpoint inhibitors such as anti-programmed cell death protein 1 (PD-1) and its ligand anti-programmed death ligand 1 (PD-L1) have shown clinical efficacy in the treatment of multiple cancers. However, there are only a few studies on biomarkers for these targeted immunotherapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Liangliang, Xie, Shengzhi, Wang, Lingxiong, Li, Jinfeng, Han, Lu, Qin, Boyu, Zhang, Guoqing, Wu, Qiyan, Gao, Wenjuan, Zhang, Lijun, Wei, Huafeng, Liu, Tianyi, Jiao, Shunchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072287/
https://www.ncbi.nlm.nih.gov/pubmed/33912192
http://dx.doi.org/10.3389/fimmu.2021.665147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072287/
https://www.ncbi.nlm.nih.gov/pubmed/33912192
http://dx.doi.org/10.3389/fimmu.2021.665147

Ejemplares similares